IFNG and cancer: Type-II interferon (IFN-γ) inflammatory signaling induces PD-L1 expression on cancer cells, conducive for tumor immune evasion, and at the same time upregulates chemokines such as CXCL9/CXCL10 that recruit CXCR3+ effector T cells as a cytotoxic response to cancer [47,48].